Clinical Trial Update: Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication [Phase 4]

View source ↗

Summary

Phase 4 clinical trial examining switching to TAF+FTC+BIC in HIV-1-infected patients over 65 at risk of polypharmacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TAF/FTC/BIC (tenofovir alafenamide/emtricitabine/bictegravir)

Snippet

Sponsor: Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | Conditions: HIV Infections | Phase 4 | Status: UNKNOWN